Cargando…

Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial

Bergamot has been traditionally used for the relief of diseases related to oxidative stress. Our aim was to investigate the effect of bergamot phytosome on visceral adipose tissue (VAT) and on metabolic profile, in overweight and obese subjects with mild hypercholesterolemia. A total of 64 participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rondanelli, Mariangela, Peroni, Gabriella, Riva, Antonella, Petrangolini, Giovanna, Allegrini, Pietro, Fazia, Teresa, Bernardinelli, Luisa, Naso, Maurizio, Faliva, Milena Anna, Tartara, Alice, Gasparri, Clara, Infantino, Vittoria, Perna, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246838/
https://www.ncbi.nlm.nih.gov/pubmed/33188552
http://dx.doi.org/10.1002/ptr.6950
_version_ 1783716394393665536
author Rondanelli, Mariangela
Peroni, Gabriella
Riva, Antonella
Petrangolini, Giovanna
Allegrini, Pietro
Fazia, Teresa
Bernardinelli, Luisa
Naso, Maurizio
Faliva, Milena Anna
Tartara, Alice
Gasparri, Clara
Infantino, Vittoria
Perna, Simone
author_facet Rondanelli, Mariangela
Peroni, Gabriella
Riva, Antonella
Petrangolini, Giovanna
Allegrini, Pietro
Fazia, Teresa
Bernardinelli, Luisa
Naso, Maurizio
Faliva, Milena Anna
Tartara, Alice
Gasparri, Clara
Infantino, Vittoria
Perna, Simone
author_sort Rondanelli, Mariangela
collection PubMed
description Bergamot has been traditionally used for the relief of diseases related to oxidative stress. Our aim was to investigate the effect of bergamot phytosome on visceral adipose tissue (VAT) and on metabolic profile, in overweight and obese subjects with mild hypercholesterolemia. A total of 64 participants were randomized into two groups for 12 weeks: a supplemented group (33 individuals, BMI 27 ± 3 kg/m(2) receiving 500 mg of bergamot phytosome, two daily tablets) and placebo group (31 subjects, BMI 28 ± 3 kg/m(2), two daily tablets). As to the within differences, the parameters of VAT, total and LDL‐cholesterol were significantly decreased in the bergamot phytosome group, but not in the placebo group. As to between‐group differences, a statistically significant interaction between time and group, that is, the change in score over time differs between the two groups was observed 30 days after supplementation for VAT (p‐value = .005), total cholesterol (p‐value <.0002), and LDL (p = .004) in respect to placebo. The other parameters (glucose, insulin, Homeostasis Model Assessment, high‐density lipoprotein cholesterol, triglycerides, fat free mass, fat mass) were not significant. In conclusion, this clinical study gives evidence that bergamot phytosome provides beneficial effects, such as decrease of VAT and modulation of metabolic alterations, after just 30 days of supplementation, resulting a very promising protection of cardiovascular health.
format Online
Article
Text
id pubmed-8246838
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-82468382021-07-02 Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial Rondanelli, Mariangela Peroni, Gabriella Riva, Antonella Petrangolini, Giovanna Allegrini, Pietro Fazia, Teresa Bernardinelli, Luisa Naso, Maurizio Faliva, Milena Anna Tartara, Alice Gasparri, Clara Infantino, Vittoria Perna, Simone Phytother Res Research Articles Bergamot has been traditionally used for the relief of diseases related to oxidative stress. Our aim was to investigate the effect of bergamot phytosome on visceral adipose tissue (VAT) and on metabolic profile, in overweight and obese subjects with mild hypercholesterolemia. A total of 64 participants were randomized into two groups for 12 weeks: a supplemented group (33 individuals, BMI 27 ± 3 kg/m(2) receiving 500 mg of bergamot phytosome, two daily tablets) and placebo group (31 subjects, BMI 28 ± 3 kg/m(2), two daily tablets). As to the within differences, the parameters of VAT, total and LDL‐cholesterol were significantly decreased in the bergamot phytosome group, but not in the placebo group. As to between‐group differences, a statistically significant interaction between time and group, that is, the change in score over time differs between the two groups was observed 30 days after supplementation for VAT (p‐value = .005), total cholesterol (p‐value <.0002), and LDL (p = .004) in respect to placebo. The other parameters (glucose, insulin, Homeostasis Model Assessment, high‐density lipoprotein cholesterol, triglycerides, fat free mass, fat mass) were not significant. In conclusion, this clinical study gives evidence that bergamot phytosome provides beneficial effects, such as decrease of VAT and modulation of metabolic alterations, after just 30 days of supplementation, resulting a very promising protection of cardiovascular health. John Wiley & Sons, Ltd. 2020-11-13 2021-04 /pmc/articles/PMC8246838/ /pubmed/33188552 http://dx.doi.org/10.1002/ptr.6950 Text en © 2020 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Rondanelli, Mariangela
Peroni, Gabriella
Riva, Antonella
Petrangolini, Giovanna
Allegrini, Pietro
Fazia, Teresa
Bernardinelli, Luisa
Naso, Maurizio
Faliva, Milena Anna
Tartara, Alice
Gasparri, Clara
Infantino, Vittoria
Perna, Simone
Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title_full Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title_fullStr Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title_full_unstemmed Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title_short Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial
title_sort bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class i subject with mild hypercholesterolemia: a randomized placebo controlled trial
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246838/
https://www.ncbi.nlm.nih.gov/pubmed/33188552
http://dx.doi.org/10.1002/ptr.6950
work_keys_str_mv AT rondanellimariangela bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT peronigabriella bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT rivaantonella bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT petrangolinigiovanna bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT allegrinipietro bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT faziateresa bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT bernardinelliluisa bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT nasomaurizio bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT falivamilenaanna bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT tartaraalice bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT gasparriclara bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT infantinovittoria bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial
AT pernasimone bergamotphytosomeimprovedvisceralfatandplasmalipidprofilesinoverweightandobeseclassisubjectwithmildhypercholesterolemiaarandomizedplacebocontrolledtrial